Trial Profile
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms HORIZON
- Sponsors Oncopeptides
- 01 Sep 2023 Results of longer follow-up analysis assessing prognostic subgroups impacting survival in updated data from two clinical trials OCEAN and HORIZON Studies published in the Clinical Lymphoma, Myeloma & Leukemia
- 27 Oct 2022 This trial has been discontinued in Spain (Date of the global end of the trial : 11-Nov-2021), according to European Clinical Trials Database record.
- 01 Sep 2022 Results assessing comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 study, belantamab mafodotin in DREAMM-2, selinexor plus dexamethasone in STORM Part 2 and melphalan flufenamide plus dexamethasone in HORIZON study published in the Clinical Lymphoma, Myeloma & Leukemia